Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$198.77M-32.5%$189.25M-3.8%$316.77M$264.54M$294.37M
$379.78M$349.72M$391.3M
$4.68M$5.04M$5.54M
$419.71M$397.13M$422.06M
$12.39M+248%$10.78M+1,080%$10.93M$6.84M$3.56M
$21.24M$22.56M$22.11M
$78.01M$42.16M$42.62M
$50K$49K$48K
-$513.76M-$489.55M-$454.98M
$341.7M$354.97M$379.44M
$419.71M$397.13M$422.06M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Maze Therapeutics, Inc. Common Stock's total assets?
Maze Therapeutics, Inc. Common Stock (MAZE) holds $419.7M in total assets, up 26.1% year over year.
How much debt does Maze Therapeutics, Inc. Common Stock have?
Maze Therapeutics, Inc. Common Stock carries $61.2M in total debt against $341.7M of shareholders' equity, a debt-to-equity ratio of 0.18.
How much cash does Maze Therapeutics, Inc. Common Stock have?
Maze Therapeutics, Inc. Common Stock holds $198.8M in cash and equivalents.
Can Maze Therapeutics, Inc. Common Stock cover its short-term obligations?
Its current ratio is 17.88 — current assets exceed current liabilities.
Where does Maze Therapeutics, Inc. Common Stock's balance sheet data come from?
Every line is extracted from Maze Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.